Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
Eli Lilly Stock: Bear Vs. Bull
08:45am, Monday, 17'th Jul 2023
Eli Lilly is adept at discovering and developing new medicines. The company's potential for innovation is bearing fruit.
Eli Lilly Buys Versanis to Boost Its Obesity Drug Portfolio
04:55pm, Friday, 14'th Jul 2023
Eli Lilly agreed to buy biopharma firm Versanis for up to $1.93 billion, boosting Lilly's reach into the obesity drug market.
Eli Lilly to expand in obesity drugs with $1.925 billion acquisition of Versanis Bio
01:51pm, Friday, 14'th Jul 2023
Shares of Eli Lilly & Co (NYSE: LLY) gained nearly 4.0% today after the pharmaceutical behemoth said it will buy Versanis Bio for up to $1.925 billion. Other financial details are yet to be disclosed
Why Eli Lilly Stock Is Rising Today
12:43pm, Friday, 14'th Jul 2023
Eli Lilly has agreed to buy privately owned Versanis Bio in a deal that could be worth up to $1.93 billion. Through this deal, Lilly will gain a novel mid-stage weight loss candidate known as bimagrum
Eli Lilly to acquire obesity drug maker Versanis for $1.9 billion
11:20am, Friday, 14'th Jul 2023
The deal is Eli Lilly's latest attempt to capitalize on the weight loss industry gold rush, which was sparked by demand for Novo Nordisk's Wegovy and Ozempic.
LLY Stock Alert: What to Know as Eli Lilly Acquires Versanis Bio
10:29am, Friday, 14'th Jul 2023
Eli Lilly (NYSE: LLY ) stock is a hot topic among traders on Friday after the company announced its acquisition of Versanis Bio . Versanis Bio is a clinical-stage biopharmaceutical company developing
Eli Lilly spends up to $1.93B to acquire obesity drug developer Versanis
09:56am, Friday, 14'th Jul 2023
Eli Lilly and Co (NYSE:LLY) announced on Friday that it will buy privately held drug developer Versanis for up to $1.93 billion, in a bid to improve its portfolio of obesity drugs. Under the terms of
Eli Lilly to Acquire Versanis Bio, Maker of Obesity Treatment
08:55am, Friday, 14'th Jul 2023
Versanis shareholders could receive as much as $1.925 billion in cash, which will consist of an upfront payment and additional payments if certain milestones are reached.
Lilly to buy Versanis for up to $1.93 bln to boost obesity drug portfolio
08:14am, Friday, 14'th Jul 2023
Eli Lilly and Co said on Friday it will acquire privately held drug developer Versanis for up to $1.93 billion, in a bid to boost its portfolio of obesity drugs.
Eli Lilly to acquire Versanis Bio, expanding obesity-treatment pipeline
08:14am, Friday, 14'th Jul 2023
Eli Lilly and Co. LLY, -1.34% will acquire Versanis Bio, a private clinical-stage biopharma company focused on new treatments for cardiometabolic diseases, the companies said in a release Friday. Vers
Uninsured Americans pay high costs for an insulin Eli Lilly vowed to price at $25, Sen. Warren says
04:38pm, Thursday, 13'th Jul 2023
Warren said the report shows that Congress needs to take additional steps to reduce the excessive prices of insulin from Eli Lilly, Sanofi and Novo Nordisk.
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
01:37pm, Thursday, 13'th Jul 2023
An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.
Uninsured US patients pay up to $330 for Eli Lilly's $25 insulin, Senator Warren says
07:03am, Thursday, 13'th Jul 2023
Americans without health insurance pay an average of $98 for Eli Lilly's generic insulin despite the company's May 1 pledge to cut its list price to $25 per vial, according to a survey of more than 30
Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say
03:59pm, Wednesday, 12'th Jul 2023
The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts s
EU medicines regulator is reviewing weight-loss drugs Ozempic and Wegovy for risk of suicidal thoughts and self-harm
01:34pm, Tuesday, 11'th Jul 2023
The European Medicines Agency said Tuesday it's reviewing data on the risk of suicidal thoughts and self-harm stemming from the use of the new medicines called GLP-1 receptor agonists, that are used t
